SCHEMBL21297244

SCHEMBL21297244

CCc1cncc(NC2CCN(C(C)=O)CC2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.52
CYP11B1 P15538 2/20 0.48
CYP11B2 P19099 2/20 0.48
RIPK2 O43353 2/20 0.45
SMYD3 Q9H7B4 1/20 0.43
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HTT P42858 2/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PRMT5 O14744 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15829849 0.83 CYP11B1 (0.51) MAPTCYP11B1CYP11B2RIPK2PRMT5
SCHEMBL17560098 0.81 MAPT (0.48) MAPTCYP11B1CYP11B2RIPK2ALDH1A1
SCHEMBL17560212 0.81 KDM4E (0.50) MAPTCYP11B1CYP11B2RIPK2ALDH1A1
SCHEMBL17303754 0.81 KDM4E (0.58) MAPTALDH1A1KDM4EHTTUSP2
SCHEMBL16217400 0.80 CYP11B1 (0.48) MAPTCYP11B1CYP11B2RIPK2ALDH1A1
SCHEMBL17308595 0.80 MEN1 (0.45) CYP11B1CYP11B2NPSR1MEN1GAA
SCHEMBL18466156 0.80 CYP11B1 (0.48) MAPTCYP11B1CYP11B2RIPK2ALDH1A1
SCHEMBL22678655 0.78 CYP11B1 (0.47) MAPTCYP11B1CYP11B2RIPK2ALDH1A1
SCHEMBL20044931 0.78 CYP11B1 (0.47) MAPTCYP11B1CYP11B2RIPK2ALDH1A1
SCHEMBL23684182 0.77 ALDH1A1 (0.46) MAPTCYP11B1CYP11B2RIPK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10391089-B2 PRMT5 inhibitors and uses therof Epizyme, Inc. (US) 2019-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10391089-B2 PRMT5 inhibitors and uses therof PRMT5, PRMT1, PRMT6 MAPT 2222/4885CYP11B1 2434/4885CYP11B2 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.